Ann Dermatol.  2014 Oct;26(5):645-646. 10.5021/ad.2014.26.5.645.

Toxic Epidermal Necrolysis in a Patient with HLA-B*5901 Haplotype Caused by Topical and Oral Carbonic Anhydrase Inhibitors

• Cheon M
• Lee YB
• Yu DS
• Kim JW

• KMID: 2265508
• DOI: http://doi.org/10.5021/ad.2014.26.5.645

Abstract

No abstract available.

MeSH Terms

Carbonic Anhydrase Inhibitors*
Haplotypes*
Humans
Stevens-Johnson Syndrome*
Carbonic Anhydrase Inhibitors

Figure

• 

  Fig. 1 (A) Coalescent erythematous macules, papules, and patches with vesicles on the face. (B) Widespread sheet-like epidermolytic detachment on the dorsum. (C) Histopathologic findings show subepidermal bullae, diffuse epidermal necrosis, and mild upper dermal inflammatory infiltrations on high-power view (H&E, ×200).

Reference

1. Harr T, French LE. Stevens-Johnson syndrome and toxic epidermal necrolysis. Chem Immunol Allergy. 2012; 97:149–166.

2. Mincione F, Scozzafava A, Supuran CT. The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008; 14:649–654.

3. Kim SH, Kim M, Lee KW, Kim SH, Kang HR, Park HW, et al. HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics. 2010; 11:879–884.

4. Chun JS, Yun SJ, Lee JB, Kim SJ, Won YH, Lee SC. Toxic epidermal necrolysis induced by the topical carbonic anhydrase inhibitors brinzolamide and dorzolamide. Ann Dermatol. 2008; 20:260–262.

5. Lee KW, Oh DH, Lee C, Yang SY. Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Tissue Antigens. 2005; 65:437–447.